⁦@US_FDA⁩ ‘s Withdrawal of Later-Line Indication For #Olaparib in #BRCA Mutated #OvarianCancer ⁦@OncLive⁩ #gyncsm #womenshealth #cancerresearch #PARP https://t.co/MY9RghtCLp (@LguzzardiM)

.@neerajaiims, of @huntsmancancer, speaks on the significance of the approval and how the combination of talazoparib and enzalutamide will fit into the treatment landscape of HRR gene–mutated mCRPC. #pcsm https://t.co/xbusmBgW8j (@OncLive)

PAVO: A Pan-Tumor PALB2 PARP Inhibitor Study -- A Single-Arm Phase-II Study of Niraparib in Locally Advanced or Metastatic Solid Tumor Patients with PALB2 Mutations - @TempusLabs @GSK https://t.co/L3jMTYj5RW #NCT05169437 #PrecisionMedicine https://t.co/SlEmF3meSl (@mtmdphd)

For patients with HRR gene–mutated mCRPC, additional data supporting the use of the combination of the PARP inhibitor talazoparib with enzalutamide is a welcome signal in the field. @neerajaiims @huntsmancancer #pcsm https://t.co/QMXZaAaaoU (@OncLive)

Perfectly timed mentor-mentee paper in @CCR_AACR from @TimothyJBrownMD & @KReissMD The Clinical Implications of Reversions in Patients with Advanced #PancreaticCancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 After Progression on Rucaparib https://t.co/rzYy2fOk24 (@Aiims1742)

Agarwal Discusses FDA Approval of Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC @neerajaiims @huntsmancancer @ASCO #ASCO23 #pcsm https://t.co/IIAaAi2fho (@OncLive)

The addition of Talazoparib(PARPi) to enzalutamide in CRPC has most marked effects in BRCA+ve tumors. Effects in the remaining HRR population are marginal. This is largely consistent with previous data for PARPi in CRPC, supporting the ODAC decision on olaparib #ACScancerchat (@tompowles1)

WATCH: A panel of expert oncologists review standard-of-care treatment approaches for HR+/HER2- early breast cancer and genetic testing practices when utilizing PARP inhibitors. @dradityabardia @DrVKGadi @jhaveri_komal @wadavidal #bcsm https://t.co/yMz2cyhcUb (@OncLive)

Agree! In the context of the addition of Talazoparib (PARPi) to enzalutamide in castration-resistant prostate cancer (CRPC), it appears that the most significant effects are observed in tumors that are BRCA positive. However, the effects in the remaining population with… https://t.co/j3Kyx4NTSd (@nataliagandur)

Read Now: Physicians Discuss When to Use a PARP Inhibitor in #mCRPC. #pcsm | @DanaFarber @CaPsurvivorship https://t.co/IdwXsamw8i (@TargetedOnc)

Here, @DrChoueiri MD, joins the @OncBrothers, Rohit Gosain, MD, and Rahul Gosain, MD, to discuss recent updates from TALAPRO-2, which studied #talazoparib plus #enzalutamide in first-line #mCRPC. #pcsm | @DanaFarber https://t.co/7zhmpcYZkN (@TargetedOnc)

Olaparib 💊 for neoadjuvant treatment of ovarian cancer!? In this podcast @ShannonWestin discusses with @pedroramirezMD the NOW trial 💥 📌https://t.co/5i99X3tfl4 @IJGConline @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @IJGCfellows @GynMe4 (@GuidoReyv)

Awesome talk by Dr. @DrRanaMcKay on the future perspectives of new drugs and compounds in RCC, highlighting antibody drug conjugates, radio pharmaceutical agents, PARP inhibitors and CDK4/6 inhibitors. #KCRS23 @OncoAlert (@FabioSchutz78)

Looking to gain CME credit while improving your clinical practice? This #MedEd course on targeting advanced prostate cancer with PARP inhibitors is; ▶️Accredited ▶️Free ▶️Expert led https://t.co/rnfFPttqU6 Our thanks to expert contributors @AttardLab, @TDorffOnc, and Fred Saad (@guconnectinfo)

🎥@AarmstrongDuke of @DukeCancer shares exciting findings from PROpel trial in mCRPC: Abiraterone + Olaparib shows improved rPFS without impacting HRQoL: ➡️https://t.co/7p9FFyoogR #PCSM #UroOnc #ASCO2023 @ASCO (@VJOncology)

#Ipatasertib plus #rucaparib has a manageable safety profile but did not show synergistic or additive antitumor activity in previously treated patients with #mCRPC. @jorgedgallo3 @HowardGurney https://t.co/uS8fdu1XcX (@CCR_AACR)

Interim overall survival analysis of #TRITON3: Rucaparib vs physician's choice in #mCRPC with homologous recombination deficiency. @AlanBryce9 @MayoClinic joins @CaPsurvivorship @DanaFarber in this discussion on UroToday > https://t.co/W19OPtRAfq @clovisoncology @FoundationATCG (@urotoday)

#TALAPRO2 study reveals efficacy and tolerability of talazoparib combination for #ProstateCancer. @neerajaiims @huntsmancancer and @CaPsurvivorship @DanaFarber discuss the importance of these findings in informing clinical practice. #WatchNow on UroToday > https://t.co/Ik6IroahO4 (@urotoday)

Dr. Cora Sternberg (@cnsternberg) sat down with @urotoday to discuss the TALAPRO-2 #ClinicalTrial evaluating talazoparib and enzalutamide for metastatic castration-resistant #ProstateCancer. Results from this study recently led to approval by the @US_FDA: https://t.co/WElMYP2tba (@WCMGUcancer)

A/Prof @AzadOncology on PARP Inhibitors in Metastatic Castration Resistant #ProstateCancer: For A Few, Some or All? | #ANZUP23 @gu_onc @PeterMacCC (@MarcDiocera)

Second-line maintenance therapy with niraparib improved overall survival vs active surveillance in patients with recurrent BRCA wild-type ovarian cancer. @rcoledude #ovca #ASCO23 https://t.co/MNEYhPArVr (@OncLive)

#FeatureFriday Today on #FeatureFriday, we are featuring a tweet by Dr. Milind Javle [@JavleMilind] about how the PBRM1 mutated biliary tract cancer subtypes aid in predicting sensitivity to PARP inhibitors. #MedTwitter (@4baseCare)

NRG-GY012 Study Tests Multiple Olaparib Combinations in Endometrial Cancer https://t.co/iA3GZYAvc7 via @targetedonc (@NCCH_MD)

Exciting news in #mCRPC research! Join @CaPsurvivorship @DanaFarber and Fred Saad, MD, FRCS @chumontreal as they discuss the #PROpel trial's final OS data, showing a 7.4-month improvement in pts who received abiraterone and olaparib. #WatchNow > https://t.co/WTPVLZ4Wa5 (@urotoday)

Great podcast on TALAPRO-2 and PARP inhibitors in prostate cancer with @neerajaiims https://t.co/XQ9Gdb6xU4 (@brian_rini)

FDA aprova talazoparibe + enzalutamida para câncer de próstata metastático resistente à castração A eficácia foi avaliada no TALAPRO-2, com melhora na SLPr na população com alteração de HRR #prostatecancer @drdanielvargas @rcarvalhoonco @FabioSchutz78 https://t.co/LBMzNXhrk0 (@MOCBrasil)

Examine #PARPinhibitors in advanced #ovariancancer with @LDuska and @DebbieRic23 in this #MedEd activity as they discuss data, diagnostic testing, and patient-centered care: https://t.co/NWEQSglBzd Produced in partnership with @NOCC_National #MedTwitter (@PeerView)

WATCH: @DrScottTagawa chatted with @OncLive about the use of PARP inhibitors for metastatic castration-resistant #ProstateCancer: https://t.co/FTEGtk9eQX (@WCMGUcancer)

@riess_md discusses the future of PARP inhibitors in lung cancer. Hopeful to have much more to discuss during this panel at #DAVAHawaiiLung 2024! https://t.co/KLXmZjByKp (@KE_Gallaway)

Second-line maintenance therapy with niraparib improved overall survival vs active surveillance in patients with recurrent BRCA wild-type ovarian cancer. @rcoledude #ovca #ASCO23 https://t.co/Ggf2NEur0I (@OncLive)

PARP inhibitor + AR signaling inhibitor combinations: Will this be the future of #mCRPC first-line therapy? #LibraryResource @RKSayyid @UofT and @zklaassen_md @GACancerCenter discuss data from the #PROpel, #MAGNITUDE, and #TALAPRO2 trials on UroToday > https://t.co/Lel4jqTXoV (@urotoday)

A new #prostatecancer webinar is happening this TODAY! This time, our topic is PARP inhibitors: What's a PARP-Inhibitor, and what does it do? Do PARP-I's work for everybody? Dr. Pamela Munster and Dr. Neal Shore will be here to fill you in https://t.co/755sLoxQkJ @bernmunster (@ancan501c3)

New #prostatecancer webinar happening this Thursday! This time, our topic is PARP inhibitors: What's a PARP-Inhibitor, and what does it do? Do PARP-I's work for everybody? Dr. Pamela Munster and Dr. Neal Shore will be here to fill you in https://t.co/755sLoxQkJ @bernmunster (@ancan501c3)

Post-ASCO Lung Cancer: In this video, Drs. @JackWestMD, @christine_lovly, and @Alfdoc2 discuss whether adding a PARP inhibitor is beneficial to patients with small cell lung cancer (SCLC). https://t.co/1OD3uPajYQ For more, please visit https://t.co/7Xpzj7KaFx. (@cancerGRACE)

Guest expert Fred Saad joins esteemed GU CONNECT members Tanya Dorff, Gerhardt Attard, & Neeraj Agarwal to discuss incorporating PARP inhibitors into prostate cancer clinical practice. 👉https://t.co/7G0cfIat1L Optional CME credit available @TDorffOnc @AttardLab @neerajaiims (@guconnectinfo)

SWOG S1929; ASCO23 SLFN11陽性のES-SCLCに対する維持治療として, アテゾリズマブとPARP阻害薬talazoparibの併用療法の有効性をみたPII試験です. PFSでは有意差がついていますが, OSは有意差がありませんでした. #ASCO23　＃小細胞肺癌 (@ZhgNHUVKOZq0IYN)

FDA Approves #Talazoparib Plus #Enzalutamide for HRR Gene–Altered #mCRPC https://t.co/5FyjMzzPcY via @onclive (@a_nourallah)

FDA Approves Talazoparib Plus Enzalutamide for HRR Gene–Altered mCRPC https://t.co/tZeYsWh070 a través de @onclive (@urogomez_)

Learn about PARP inhibitors in prostate cancer from experts Alicia Morgans & Pasquale Rescigno. @CaPsurvivorship @PasRescigno Find the micro learning programme here: 👉https://t.co/R8mMarkrX5 Includes videos, slides, flashcards & CME credit assessments Endorsed by @ZEROCancer (@guconnectinfo)

Post-ASCO Lung Cancer: In this video, Drs. @JackWestMD, @christine_lovly, and Alfredo Addeo discuss whether adding a PARP inhibitor is beneficial to patients with small cell lung cancer (SCLC). https://t.co/1OD3uPajYQ For more, please visit https://t.co/3VETMT8eM4. (@cancerGRACE)

Incredibly stimulating talk by @KReissMD about her cyclical bench to bedside investigations on survival and immunological outcomes of treating #PancreaticCancer with #PARP inhibitors and immune checkpoint blockades (@OHSUpancreatic)

🎥@vanderweelemd shares findings on DDR and PARP inhibition in prostate cancer: BRCA1/2 and HRR genes are vital prognostic biomarkers, TALAPRO-2 trial strengthens BRCA1/2 as predictive markers, LuPARP trial demonstrates olaparib's safety in mCRPC https://t.co/Qsi0Ac26ZF #ASCO23 (@VJOncology)